U.S. Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals), By End-use (Home, Hospitals), And Segment Forecasts, 2025 - 2030

U.S. Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals), By End-use (Home, Hospitals), And Segment Forecasts, 2025 - 2030


U.S. Intravenous Solutions Market Growth & Trends

The U.S. intravenous solutions market size is anticipated to reach USD 7.91 billion by 2030 and is projected to grow at a CAGR of 7.8% during the forecast period, according to a new report by Grand View Research, Inc. The market is experiencing growth due to the increasing prevalence of disease and a rise in surgical procedures. The aging population, which is more prone to non-communicable diseases such as cancer, neurological, cardiovascular disorders, and spinal injuries, is also driving market expansion. In October 2024, Fresenius Medical Care announced initiatives to mitigate disruptions in dialysis care. The company is enhancing the production of PD and IV solutions by leveraging its global production facilities. Prompted by the Department of Health & Human Services, Fresenius Medical Care is committed to meeting the demand for IV fluids and peritoneal dialysis (PD) products through improved production strategies.

IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.

U.S. Intravenous Solutions Market Report Highlights
  • The total parenteral nutrition (TPN) type segment held the largest revenue share of 67.14% in 2024 due to its critical role in providing essential nutrients directly into the bloodstream for patients who cannot consume food orally or absorb nutrients through their gastrointestinal tract.
  • Based on nutrients, the single-dose amino acid solution segment dominated the segment with a market share of 31.33% in 2024 as it offers a convenient and effective means of delivering protein directly to patients. These solutions are tailored to specific patient needs, ensuring that they receive adequate amino acids necessary for recovery and maintenance of bodily functions.
  • The vitamins & minerals segment is expected to grow at the fastest CAGR over the forecast period. These micronutrients are essential for various metabolic processes and overall health, particularly in patients receiving TPN or other forms of parenteral nutrition.
  • In terms of end use, the hospitals segment dominated the segment with a market share of 46.0% in 2024 due to their critical role in acute care settings. Hospitals require a steady supply of intravenous solutions for various medical procedures, including surgeries and emergency care, making them essential players in this market.
  • The home segment is expected to grow at the fastest CAGR over the forecast period due to an increasing preference for at-home treatments, which are more convenient and cost-effective for patients.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Therapy Type Segment
1.1.2. Therapeutic Area Segment
1.2. Country Scope
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Primary Research
1.6. Information or Data Analysis:
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. List of Abbreviations
1.11. Objective
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rise in number of clinical studies for cellular therapies in Asia Pacific
3.2.1.2. Expanding regenerative medicine landscape in Asian countries
3.2.1.3. Introduction of novel platforms and technologies
3.2.2. Market Restraint Analysis
3.2.2.1. Ethical concerns
3.2.2.2. Clinical issues pertaining to development & implementation of cell therapy
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Therapy Type Business Analysis
4.1. Therapy Type Segment Dashboard
4.2. Asia Pacific cell therapy market: Therapy Type Movement Analysis
4.3. Asia Pacific cell therapy market Size & Trend Analysis, by Therapy Type, 2018 to 2030 (USD Million)
4.4. Allogeneic Therapies
4.4.1. Allogeneic therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.2. Stem Cell Therapies
4.4.2.1. Stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Hematopoietic Stem Cell Therapies
4.4.2.2.1. Hematopoietic stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Mesenchymal Stem Cell Therapies
4.4.2.3.1. Mesenchymal stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.3. Non-stem Cell Therapies
4.4.3.1. Non-stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.3.2. Keratinocytes & Fibroblast-based Therapies
4.4.3.2.1. Keratinocytes & fibroblast-based therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.3.3. Others
4.4.3.4. Others market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Autologous Therapies
4.5.1. Autologous therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.2. Stem Cell Therapies
4.5.2.1. Stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.2.2. BM, Blood, & Umbilical Cord-derived Stem Cells
4.5.2.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.2.3. Adipose derived cells
4.5.2.3.1. Adipose derived cells market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.2.4. Others
4.5.2.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.3. Non-Stem Cell Therapies
4.5.3.1. Non-stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.3.2. T-Cell Therapies
4.5.3.2.1. T-Cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.3.2.2. CAR T Cell Therapy
4.5.3.2.2.1. CAR T cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.3.2.3. T Cell Receptor (TCR)-based
4.5.3.2.3.1. T cell receptor (TCR)-based market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.3.3. Others
4.5.3.3.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Therapeutic Area Business Analysis
5.1. Therapeutic Area Segment Dashboard
5.2. Asia Pacific cell therapy market Therapeutic Area Movement Analysis
5.3. Asia Pacific cell therapy market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Cardiovascular Disease (CVD)
5.5.1. Cardiovascular disease (CVD) market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Musculoskeletal Disorders
5.6.1. Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
5.7. Dermatology
5.7.1. Dermatology market estimates and forecasts, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Country Business Analysis by Therapy Type, Therapeutic Area
6.1. Country Dashboard
6.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
6.3. Asia Pacific
6.3.1. Asia Pacific cell therapy market, 2018 - 2030 (USD Million)
6.3.2. Japan
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Japan cell therapy market, 2018 - 2030 (USD Million)
6.3.3. China
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. China cell therapy market, 2018 - 2030 (USD Million)
6.3.4. India
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. India cell therapy market, 2018 - 2030 (USD Million)
6.3.5. Australia
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Australia cell therapy market, 2018 - 2030 (USD Million)
6.3.6. South Korea
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. South Korea cell therapy market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Kolon TissueGene, Inc.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. JCR Pharmaceuticals Co., Ltd.
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. MEDIPOST
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. PHARMICELL Co., Ltd.
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. ANTEROGEN. CO., LTD
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Bristol-Myers Squibb Company
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Novartis AG
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Gilead Sciences, Inc.
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Curocell, Inc.
7.4.9.1. Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. JW Therapeutics (Shanghai) Co., Ltd.
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. STEMPEUTICS RESEARCH PVT LTD
7.4.11.1. Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings